Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic

by bizlift | Apr 2, 2020 | Denali Press Releases, Portfolio News

Denali Therapeutics Announces Pricing of Public Offering of Common Stock

by bizlift | Jan 29, 2020 | Denali Press Releases, Portfolio News

Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights

by bizlift | Nov 6, 2019 | Denali Press Releases, Portfolio News

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website

by bizlift | Sep 4, 2019 | Denali Press Releases, Portfolio News

Denali Therapeutics Announces that its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

by bizlift | Aug 5, 2019 | Denali Press Releases, Portfolio News

Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs

by bizlift | Jun 11, 2019 | Denali Press Releases, Portfolio News